iShares MSCI Switzerland ETF (EWL)
Switzerland Rejects Forced Labor Accusations After U.S. Imposes New Tariffs
Switzerland refuted U.S. allegations over forced labor after the Trump administration imposed a new 12.5% tariff on imports of Swiss goods.
SNB to keep rates at 0% this year and probably in 2027, economists say
The Swiss National Bank will keep its key policy rate at 0% on June 18 and for the rest of the year, according to all the economists who responded to a Reuters poll, as a stronger franc partly offset the impact of the energy price shock related to the U.S. war on Iran.
Swiss Referendum: Voters Reject 10 Million Population Cap Proposal
Swiss voters rejected a proposal to cap the country's population at 10 million people as economic risks overcame elevated concerns about immigration. A 55% majority accepted warnings from companies and the government that the proposal would have a long-term negative impact on growth.
Swiss pharma hub Basel frets over population cap threat
For decades, economic growth in Basel has outpaced that of Switzerland as its globe-straddling pharmaceutical and biotech industries have turned the city on the border with Germany and France into one of the most prosperous in Europe.
Swiss Biotech sector boosted by shift toward private funding, report says
Switzerland's biotech industry shifted toward private financing in 2025 as funding from capital markets remained difficult to obtain and pharmaceutical companies sought out collaborative deals with biotech firms, a report on the sector showed on Tuesday.
EWL: No Energy, Light On Tech, Premium P/E
I maintain a Hold rating on iShares MSCI Switzerland ETF (EWL) due to its premium valuation and mixed technicals. EWL trades at 18.1x earnings with a PEG near 3, limiting its current valuation appeal despite a 14.5% 12-month gain. The ETF is highly liquid, top-heavy in Health Care (notably Novartis and Roche), and lacks significant Tech or Energy exposure.
1607 Capital Partners LLC Has $35.01 Million Stake in iShares MSCI Switzerland ETF $EWL
1607 Capital Partners LLC cut its stake in shares of iShares MSCI Switzerland ETF (NYSEARCA:EWL) by 8.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 633,799 shares of the exchange traded fund's stock after selling 57,090 shares during the quarter.
EWL: February Could Be Quite Big For Swiss Macro
The iShares MSCI Switzerland ETF is heavily weighted toward healthcare and financials, with some exposure to tariff negotiations, which may be more than halved. Novartis faces considerable direct tariff risk but expects mitigation by mid-2026 as its US footprint expands, while Roche and Nestle are less exposed. Financials like UBS are partly indexed to Swiss domestic macro conditions, which could benefit from lower tariffs, though global exposure tempers overall impact.
Swiss government says new 15% U.S. tariff ceiling retroactive to mid-November
The Swiss government said a deal to reduce U.S. tariffs on that country's imports to 15% will apply retroactively to Nov. 14. Switzerland has promised to invest in the U.S. economy in exchange for tariff relief.
Creative Planning Acquires 2,953 Shares of iShares MSCI Switzerland ETF $EWL
Creative Planning lifted its holdings in iShares MSCI Switzerland ETF (NYSEARCA:EWL) by 6.9% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 45,624 shares of the exchange traded fund's stock after acquiring an additional 2,953 shares during the period. Creative Planning owned approximately 0.19%
US tariffs on Swiss goods cut to 15% in deal struck with Trump administration
In exchange, Swiss officials committed to series of quotas for imports from the US on a duty-free basis
U.S. and Switzerland reach trade deal to lower tariffs to 15%
Switzerland has been subject to one of the highest tariff rates levied on an individual country by the Trump administration.
Trump's 39% tariffs ‘horrible' for Switzerland, Breitling CEO says
Georges Kern, CEO of Swiss luxury watchmaker, Breitling, speaks to CNBC's Carolin Roth about the impact of U.S. tariffs on the company, and explains how political instability across Europe has affected the business. Subscribe: @CNBCInternationalLive Subscribe to CNBC International: @CNBCInternational LinkedIn: https://www.linkedin.com/showcase/cnbc-international/ TikTok: https://www.tiktok.com/@cnbci Facebook: https://www.facebook.com/cnbcinternational Instagram: https://www.instagram.com/cnbcinternational/ Threads: https://www.threads.net/@cnbcinternational X: https://twitter.com/CNBCi Telegram: https://t.me/cnbci
U.S. and Switzerland working on a deal to slash 39% tariffs
The 39% duty was met with dismay, with business leaders saying it was damaging business. Switzerland's key exports include watches, jewelry, machinery, chocolate, and pharmaceutical products.
EWL: Why This Fund Will Likely Lag Broader International Funds
iShares MSCI Switzerland ETF receives a Hold rating due to its mixed outlook versus broader international peers and less attractive valuation. EWL's top holdings—Nestle, Novartis, and Roche—offer stability and dividend growth but lag behind the growth of global tech leaders in VXUS. EWL has higher fees (0.50%) and a lower dividend yield compared to peer funds like VXUS, which also boasts greater diversification and lower costs.
EWL: Buy Swiss, Invest Globally
EWL offers exposure to Switzerland's resilient economy, with a focus on defensive, high-quality multinationals like Nestlé, Roche, and Novartis. The fund's concentrated portfolio is balanced by sector diversification and the global reach of its top holdings, supporting steady medium-term returns. EWL's expense ratio is reasonable given its liquidity and BlackRock's reputation, though dividend yield could be higher compared to peers.
EWL: Swiss Stocks Are Expensive, But They're High Quality Compounders
iShares MSCI Switzerland ETF (EWL) offers a stake in high-quality companies in a uniquely stable and decentralized nation. The ETF is quite concentrated, with the top three and top ten holdings accounting for 40% and 66% of assets, respectively. EWL benefits from the Swiss Franc's historical and ongoing outperformance against the U.S. dollar, enhancing long-term returns.
EWL: A More Political Stable, But Too Expensive Alternative To The U.S.
Switzerland offers a stable investment environment with solid economic data, low inflation, and a healthy labor market. The iShares MSCI Switzerland ETF is expensive with a P/E ratio of 21.18 and a P/B ratio of 3.31, almost similar to the S&P 500. EWL's high allocation to Nestle, Roche, and Novartis poses diversification risks, and their low growth rates do not justify the ETF's high valuation.
EWL: Quality Swiss Blue Chips At A Fair Price
The iShares MSCI Switzerland ETF offers investors exposure to stocks listed in Switzerland. Like many country-specific funds, this ETF is very top-heavy. Sector concentration is also significant. Although this isn't a factor-based fund, its target index consists of companies that sport very high-quality earnings.
EWL: Switzerland Stocks Not Cheap Enough
A valuation gap exists between US and European equities, with European stocks, including Swiss equities, being significantly cheaper even after accounting for sector differences. I have a hold rating on the iShares MSCI Switzerland ETF due to its higher P/E ratio and recent bearish trends in the healthcare sector. EWL's technical situation is concerning, with support levels at $45 and $41.50–42.00 suggesting buying on dips rather than at current prices.